 |
|
|
prIME Oncology invites you to view abstract presentations from the 2011 Annual Hematology Meeting in San Diego provided by experts in the fields of lymphoma and multiple myeloma.
|
Abstract Presentations |
 |
Downloadable Slides |
 |
|
 |
Release Date
December 17, 2011
|
Expiration Date
December 17, 2012 |
|
| Faculty |
Bertrand Coiffier, MD, PhD
Hospices Civils de Lyon
Lyon, France
Meletios Dimopoulos, MD
University of Athens
Athens, Greece
Christopher Flowers, MD
Emory University
Atlanta, Georgia, United States
Jonathan Friedberg, MD, MMSc
University of Rochester, James P Wilmont Cancer Center
Rochester, New York, United States
Andrzej Jakubowiak, MD, PhD
University of Chicago
Chicago, Illinois, United States
Hanneke Kluin-Nelemans, MD, PhD
University Medical Center Groningen
Groningen, the Netherlands
Xavier Leleu, MD, PhD
Hospital Huriez
Lille, France
|
Sagar Lonial, MD
Emory University
Atlanta, Georgia, United States
María-Victoria Mateos, MD, PhD
University Hospital of Salamanca
Salamanca, Spain
Craig Moskowitz, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, United States
Oliver Press, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Jesús San-Miguel, MD, PhD
University Hospital of Salmanca
Salmanca, Spain
|
David Siegel, MD, PhD
John Theuer Cancer Center
Hackensack, New Jersey, United States
David Telio, MD
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Anas Younes, MD
University of Texas, M. D. Anderson Cancer Center
Houston, Texas, United States
Ravi Vij, MD
Washington University in Saint Louis
St Louis, Missouri, United States
Umberto Vitolo, MD
San Giovanni Battista Hospital
Turin, Italy
|
Target Audience
This continuing medical education activity is intended for oncologists, hematologists, and other health care providers interested in the management of hematologic malignancies.
|
Overview
These presentations discuss recently released data from the 2011 Annual Hematology Meeting in San Diego, focusing on various aspects of the management of patients with hematologic malignancies.
|
Learning Objectives
After successful completion of this educational activity, participants should be able to:
- Discuss the most recent clinical trial data regarding treatment of patients with lymphoma and multiple myeloma
- Describe emerging therapies and novel treatment strategies in lymphoma and multiple myeloma, and evaluate the practical utility of novel agents based on data from recent clinical studies
- Evaluate the use of molecular markers and patient characteristics to guide the therapeutic decision-making process in patients with hematologic malignancies
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each module may provide the following credits:
Lymphoma: 1.5 credits
Multiple myeloma
: 1.5 credits
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the video player pages.
|
Support Statement
This activity is supported by Merck & Co., Inc; Millennium: The Takeda Oncology Company; and Onyx Pharmaceuticals. |
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Faculty Disclosures
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Coiffier has disclosed that he has received consulting fees from Millennium and Johnson & Johnson. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Dimopoulos has disclosed that he has received consulting fees from for Onyx, Merck, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Flowers had disclosed that he has received consulting fees from Seattle Genetics and Spectrum. He has also performed contracted research for Spectrum, Novartis, and Millennium/Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Friedberg has disclosed that he has received consulting fees from Millennium and has performed contracted research for Onyx and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Gribben has disclosed that he has received consulting fees from Roche, Celgene, MundiPharma, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Ghobrial has disclosed that she has received consulting fees from Celgene, Millennium, Novartis, BMS, and Onyx. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jakubowiak has disclosed that he has received consulting fees from Millennium, Onyx, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Kluin-Nelemans has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Leleu has disclosed that he has received consulting fees from Celgene, Janssen, and Leopharma. He has received research grants from Celgene, Janssen, Novartis, Amgen, Roche, and Chugai. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lonial has disclosed that he has received consulting fees from Millennium, Celgene, Novartis, Bristol-Myers Squibb, Onyx, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Mateos has disclosed that she has received consulting fees from Janssen, Celgene, and Millenium. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Moscowitz has disclosed that he has received consulting fees for participation in a GSK advisory board. He has also performed contracted research for GSK. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Niesvizky has disclosed that he has received consulting fees and fees for non-CME activities from Celgene and Millennium. He has also performed contracted research for Celgene, Millennium, and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Press has disclosed that he has received consulting fees from Spectrum and Roche/Genentech and has performed contracted research for Roche/Genentech. He has ownership interest in Bioemergent Solutions. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Richardson has disclosed that he has received consulting fees from Celgene, Millenium, Johnson & Johnson, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr San Miguel has disclosed that he has received consulting fees from Celgene, Janssen, Millennium, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Siegel has disclosed that he is a member of the speakers’ bureau and advisory boards of Celgene, Millennium, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation..
Dr Telio has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Younes has disclosed that he has received consulting fees from Seattle Genetics, Novartis, Sanofi, S*Bio, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Vij has disclosed that he has received consulting fees from Onyx, Celgene, Millenium, and Novartis. He has received fees for non-CME services from Celgene, Millenium, and Novartis. He has performed contracted research for Celgene and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Vitolo has disclosed that he has received fees for non-CME services from Roche, Celgene, Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Chelsey Goins, PhD (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Heather Tomlinson, MA (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
|
|
|
|
|
|
|
|
|
|
|
|
